

Agenda

Thursday, March 7, 2024

| | |
|------------|---|
| 12:30 pm | Registration |
| 1:25 pm | Conference Introduction: Lucy Boyce Kennedy, MD & Pauline Funchain, MD |
| Session #1 | Future of irAE Management |
| Moderator: | Kasra Karamlou, MD |
| 1:30 pm | Introduction: Where are we now with irAE Management? – Kasra Karamlou, MD |
| 1:40 pm | How are Inpatient irAEs Managed at Mass General? – Kerry Reynolds, MD |
| 2:00 pm | How are Outpatient irAEs Managed at Mass General? – Krista Rubin, MS, FNP-BC |
| 2:20 pm | How are irAEs Managed at Cleveland Clinic? – Lucy Boyce Kennedy, MD |
| 2:50 pm | Challenges of irAE Management in Community Oncology Settings – Kathryn Bollin, MD |
| 3:10 pm | Panel Discussion / Q&A – Session speakers & Rebecca Sessler, RN, BSN |
| 3:40 pm | BREAK |

| | |
|------------|---|
| Moderator: | Oral Abstracts & Pharmacy Considerations |
| | Tamiko Katsumoto, MD |
| 3:55 pm | Abstract # 1 |
| 4:00 pm | Abstract # 2 |
| 4:05 pm | Q&A |
| 4:15pm | Pharmacology of Steroids – Emily Chheng, PharmD, BCOP |
| 4:30 pm | Refractory Therapies – Madison Walling, PharmD |
| 4:45 pm | Q&A |
| 5:00 pm | Wrap Up / Adjourn / Reception & Posters |

Friday, March 8, 2024

| | |
|------------|---|
| 7:30 am | Registration/ Continental Breakfast |
| 8:00 am | Welcome / Introduction |
| SESSION #1 | MANAGEMENT OF COMMON irAEs |
| Moderator: | James Isaacs, MD |
| 8:05 am | Rheumatologic irAEs – Alexa Meara, MD |
| 8:25 am | Dermatologic irAEs – Rashmi Unwala, MD |
| 8:45 am | Endocrine irAEs – Keren Zhou, MD |
| 9:05 am | Pulmonary irAEs – Michael Smith, MD |
| 9:25 am | Case Presentations / Panel Discussion / Q & A |
| 9:45 am | BREAK |

| | |
|------------|----------------------|
| SESSION #2 | KEYNOTE ADDRESS |
| Moderator: | Pauline Funchain, MD |
| 10:00 am | Rohit Moudgil, MD |
| 10:40 am | Q&A |

| | |
|------------|--|
| SESSION #3 | GUTSY FEELINGS |
| Moderator: | Jessica Philpott, MD, PhD |
| 10:50 am | Introduction |
| 10:55 am | Gastrointestinal irAEs – Joseph Sleiman, MD |
| 11:15 am | Hepatologic irAEs – Hao Chi "Joseph" Zhang, MD |
| 11:35 am | Case Presentations / Panel Discussion / Q & A |
| 11:55 am | Lunch |

| | |
|------------|--|
| SESSION #4 | SPEED ROUNDS: RECOGNITION OF UNDER APPRECIATED irAEs |
| Moderator: | Thach Giao Truong, MD |
| 1:00 pm | Introduction |
| 1:05 pm | Neurologic – Marisa McGinley, MD |
| 1:20 pm | Infectious Disease – Zachary Yetmar, MD |
| 1:35 pm | Nephrologic irAEs – Ali Mehdi, MD |
| 1:50 pm | Ophthalmologic irAEs – Sumit Sharma, MD |
| 2:05 pm | Case Presentations / Panel Discussion / Q & A |
| 2:30 pm | BREAK |

| | |
|------------|--|
| SESSION #5 | HEME |
| Moderator: | Bassam Estfan, MD |
| 2:45 pm | Introduction |
| 2:50 pm | Hematologic irAEs – Keith McCrae, MD |
| 3:10 pm | CAR T-cell and TIL Therapies – Paolo Caimi, MD |
| 3:30 pm | Case Presentations/ Panel Discussion / Q & A |
| 3:50 pm | Wrap Up / Adjourn |

Cleveland Clinic

The Cleveland Clinic Foundation
Cleveland Clinic Taussig Cancer Institute
9500 Euclid Ave. JJNG
Cleveland, OH 44195

Cleveland Clinic


Management of Checkpoint Inhibitor-Related Toxicity

Thursday-Friday, March 7-8, 2024

InterContinental Hotel & Conference Center
9801 Carnegie Avenue
Cleveland, Ohio

Register Today: www.ccfcmc.org/toxicitymgmt24

Virtual Option Available




Cleveland Clinic

Management of Checkpoint Inhibitor-Related Toxicity

Thursday-Friday, March 7-8, 2024

InterContinental Hotel & Conference Center
9801 Carnegie Avenue
Cleveland, Ohio

Register Today: www.ccfcmc.org/toxicitymgmt24
Virtual Option Available



www.ccfcmc.org/toxicitymgmt24

About the Course

Twelve checkpoint inhibitor therapies have been approved since 2011 in a wide variety of cancers, including tumor-agnostic indications for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer. Immune checkpoint blockade leads to a new spectrum of dysimmune toxicity requiring collaboration between oncologist providers and specialists to improve the understanding of the mechanism, diagnosis, and management of irAEs. Six CAR T-cell therapies have been approved since 2017 for the treatment of blood cancers, including lymphomas, some forms of leukemia, and, most recently, multiple myeloma.

Medical subspecialists, nurses, nurse practitioners, physician assistants, pharmacists, and residents/fellows are invited to attend.

Learning Objectives

- As a result of attending the course, the participant will be able to:
- Describe the mechanism of action associated with checkpoint inhibitor therapies and the biologics used in the treatment of immune-related adverse events.
 - Identify the spectrum of immune-related adverse events that can occur with immune checkpoint inhibitor therapies and CAR T-cell therapies.
 - Implement assessment criteria, diagnostic testing, and interventions to improve early identification and management of immune-related AEs.
 - Recognize the importance and necessity of the multidisciplinary approach in treatment of immune-related adverse events.

Program Location

InterContinental Hotel & Conference Center
9801 Carnegie Avenue • Cleveland, OH 44106

Hotel Information and Reservations

A block of rooms has been reserved at the InterContinental Hotel & Conference Center until 5:00 pm ET, February 19, 2024. Make your reservation by calling 855.765.8709. Please identify yourself as being with the Cleveland Clinic Immunotherapy conference for a special rate of \$199 plus tax.

Parking

Parking is available in the E 100th Street visitor’s parking garage.

Faculty Disclosure

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Integrity and Independence requiring mitigation of all faculty conflicts of interest. Faculty declaring a relevant financial relationship will be identified in the activity syllabus.

Accreditation

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

American Medical Association (AMA)

Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

NURSING STATEMENT WITH PHARMACOLOGY:

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 9.50 ANCC contact hours, which includes 9.50 pharmacology credits.

Accreditation Council of Pharmacy Education (ACPE)

Cleveland Clinic Center for Continuing Education designates this knowledge-based activity for a maximum of 9.50 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. Universal Activity Number List:
Pharmacist UAN **JA0000192-0000-24-035-L01-P**
Technician UAN **JA0000192-0000-24-035-L01-T**

Certificate of Participation

A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations. 9.50 contact hours with 5.0 pharmacology credit.

American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Information

For further information about this activity, contact Elizabeth Lindecke at
Local: 216.445.0099
Toll Free: 800.223.2273 x50099
Email: lindece@ccf.org

Faculty

Course Directors

Lucy Boyce Kennedy, MD
Department of Hematology/ Oncology
Cleveland Clinic
Cassandra M Calabrese, DO
Department of Rheumatologic and Immunologic Disease
Cleveland Clinic

Planning Committee

Pauline Funchain, MD
Melanoma and Cutaneous Oncology
Stanford University
Rebecca Sessler, RN, BSN
Specialty Care Coordinator
Cleveland Clinic, North Coast Cancer Center
Sowmya Takkellapati, PharmD, BCOP
Inpatient Pharmacy
Cleveland Clinic
Laura S. Wood, RN, MSN, OCN
Oncology Nurse Specialist
Cleveland Clinic, retired

Invited Faculty

Kathryn Bollin, MD
Clinical Assistant Professor of Medicine
Division of Hematology/Oncology, Scripps Clinic
San Diego, CA
Tamiko Katsumoto, MD
Division of Immunology and Rheumatology
Department of Medicine
Stanford University
Palo Alto, CA
Alexa Meara, MD
Associate Professor, Division of Oncology
Division Rheumatology and Immunology
The Ohio State Wexner Medical Center
Columbus, OH

Kerry Reynolds, MD
Clinical Director, Inpatient Oncology Units Director,
Severe Immunotherapy Complications Program
Massachusetts General Hospital
Boston, MA

Krista Rubin MS, FNP-BC
Nurse Practitioner, Center for Melanoma
Mass General Hospital Cancer Center
Boston, MA

Joseph Sleiman, MD
Senior Gastroenterology Fellow
Division of Gastroenterology,
Hepatology and Nutrition
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, PA

Hao Chi "Joseph" Zhang, MD
Assistant Professor
Department of Gastroenterology,
Hepatology and Nutrition
University of Texas MD Anderson Cancer Center
Houston, TX

Cleveland Clinic Faculty

Paolo Caimi, MD
Department of Hematology/ Oncology
Emily Chheng, PharmD, BCOP
Hospital Outpatient Pharmacy
Bassam Estfan, MD
Department of Hematology/ Oncology
James Isaacs, MD
Department of Hematology/Oncology
Kasra Karamlou, MD
Department Hematology/Oncology Sandusky

Lucy Boyce Kennedy, MD
Department of Hematology/ Oncology
Keith McCrae, MD
Department of Hematology/ Oncology

Marisa McGinley, MD
Mellen Center
Ali Mehdi, MD
Department of Kidney Medicine

Rohit Moudgil, MD, PhD
Department of Cardiovascular Medicine

Jessica Philpott, MD, PhD
Department of Gastroenterology,
Hepatology, & Nutrition
Rebecca Sessler, RN, BSN
Cleveland Clinic Cancer Center, Sandusky

Michael Smith, MD
Department of Pulmonary &
Critical Care Medicine


Sumit Sharma, MD
Cole Eye Institute
Thach Giao Truong, MD
Department of Hematology/ Oncology

Rashmi Unwala, MD
Department of Dermatology

Madison Walling, PharmD
Hospital Outpatient Pharmacy

Zachary Yetmar, MD
Department of Infections Disease

Keren Zhou, MD
Department of Endocrinology,
Diabetes & Metabolism



Registration Form

Management of Checkpoint Inhibitor-Related Toxicity

Thursday-Friday, March 7 & 8, 2024
InterContinental Hotel & Conference Center

Registration Fees

| Before March 1, 2024 | | After March 1, 2024 | |
|----------------------|-------|---------------------|-------|
| Physician: | \$199 | Physician: | \$250 |
| Resident / Fellow | \$0* | Resident / Fellow | \$0* |
| APP / Pharmacist | \$50 | APP / Pharmacist | \$75 |
| Nurse | \$25 | Nurse | \$30 |
| Corporate | \$199 | Corporate | \$250 |

* Letter from program chairman or department chairman must accompany Resident/Fellow registration.

Fee includes registration materials, continental breakfast, lunch, and breaks.

To register go to: www.ccfcme.org/toxicitymgmt24

Deadline for Registration & Cancellation

Register at www.ccfcme.org/toxicitymgmt24. The deadline for registration is 5:00 pm (EST), Tuesday, March 5, 2024. A request for refund must be received in writing by March 1, 2024. No refunds will be given after March 7, 2024. A \$50 cancellation fee will be deducted from the refund for cancellations after March 1, 2024. For questions about registrations, please call 216.448.8710 or email cmeregistration@ccf.org.

Americans with Disabilities Act

The Cleveland Clinic Foundation Center for Continuing Education fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify Cleveland Clinic at 216-444-7924 at least two weeks prior to the activity.